Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heidrun Bosch-Traberg

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Kidney International|February 4, 2023
Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placeboKatherine R Tuttle, Heidrun Bosch-Traberg, David Z I Cherney, et al.
Diabetes, Obesity & Metabolism|September 28, 2018
Health-related quality of life in people with type 2 diabetes participating in the LEADER trialMichael A Nauck, John B Buse, Johannes F E Mann, et al.
Diabetes Care|December 19, 2015
Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical TrialMelanie J Davies, Stephen C Bain, Stephen L Atkin, et al.
Diabetes, Obesity & Metabolism|April 5, 2019
Liraglutide use and evaluation of pancreatic outcomes in a US commercially insured populationDonnie Funch, Kathleen Mortimer, Najat J Ziyadeh, et al.
Pharmaceutical Research|June 10, 2020
Influence of Production Process and Scale on Quality of Polypeptide Drugs: a Case Study on GLP-1 AnalogsArne Staby, Dorte Bjerre Steensgaard, Kim F Haselmann, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|June 18, 2021
Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US Commercially Insured PopulationDonnie Funch, Kathleen Mortimer, Najat J Ziyadeh, et al.
The New England Journal of Medicine|May 24, 2024
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 DiabetesVlado Perkovic, Katherine R Tuttle, Peter Rossing, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 23, 2026
Effect of semaglutide on COVID-19 and other infections: an analysis from the FLOW randomized clinical trialBrian Rayner, Kenneth W Mahaffey, Johannes F E Mann, et al.
Circulation|October 26, 2018
Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin UseSubodh Verma, Lawrence A Leiter, C David Mazer, et al.
Diabetes Care|July 29, 2025
Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary AnalysisPeter Rossing, George Bakris, Vlado Perkovic, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Kidney International|February 4, 2023
Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placeboKatherine R Tuttle, Heidrun Bosch-Traberg, David Z I Cherney, et al.
Diabetes, Obesity & Metabolism|September 28, 2018
Health-related quality of life in people with type 2 diabetes participating in the LEADER trialMichael A Nauck, John B Buse, Johannes F E Mann, et al.
Diabetes Care|December 19, 2015
Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical TrialMelanie J Davies, Stephen C Bain, Stephen L Atkin, et al.
Diabetes, Obesity & Metabolism|April 5, 2019
Liraglutide use and evaluation of pancreatic outcomes in a US commercially insured populationDonnie Funch, Kathleen Mortimer, Najat J Ziyadeh, et al.
Pharmaceutical Research|June 10, 2020
Influence of Production Process and Scale on Quality of Polypeptide Drugs: a Case Study on GLP-1 AnalogsArne Staby, Dorte Bjerre Steensgaard, Kim F Haselmann, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|June 18, 2021
Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US Commercially Insured PopulationDonnie Funch, Kathleen Mortimer, Najat J Ziyadeh, et al.
The New England Journal of Medicine|May 24, 2024
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 DiabetesVlado Perkovic, Katherine R Tuttle, Peter Rossing, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 23, 2026
Effect of semaglutide on COVID-19 and other infections: an analysis from the FLOW randomized clinical trialBrian Rayner, Kenneth W Mahaffey, Johannes F E Mann, et al.
Circulation|October 26, 2018
Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin UseSubodh Verma, Lawrence A Leiter, C David Mazer, et al.
Diabetes Care|July 29, 2025
Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary AnalysisPeter Rossing, George Bakris, Vlado Perkovic, et al.
Pageof 3